How does 1530's PE Ratio compare to its peers?

1530 is good value based on its Price-To-Earnings Ratio (7.5x) compared to the peer average (26x).

How does 1530's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1530 is good value based on its Price-To-Earnings Ratio (7.5x) compared to the Asian Biotechs industry average (33x).

What is 1530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1530 is good value based on its Price-To-Earnings Ratio (7.5x) compared to the estimated Fair Price-To-Earnings Ratio (12.2x).

What is the Fair Price of 1530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1530 (HK$5.69) is trading below our estimate of [[fair value]] (HK$19.06)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

3SBio (SEHK:1530) - Stock Price, News & Analysis

1530 Stock Overview

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details

1530 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 70.1% below our estimate of its fair value

Earnings are forecast to grow 14.65% per year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

3SBio Inc. Competitors

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.8b

Shanghai Henlius Biotech

SEHK:2696

HK$11.1b

Shandong Boan Biotechnology

SEHK:6955

HK$4.6b

Essex Bio-Technology

SEHK:1061

HK$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for 3SBio
Historical stock prices
Current Share Price	HK$5.69
52 Week High	HK$7.85
52 Week Low	HK$4.91
Beta	0.70
11 Month Change	-9.68%
3 Month Change	-0.70%
1 Year Change	-23.11%
33 Year Change	-17.06%
5 Year Change	-52.58%
Change since IPO	-39.14%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 08

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

Oct 07

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Recent updates

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 08

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

Oct 07

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Shareholder Returns

	1530	HK Biotechs	HK Market
7D	-2.4%	1.5%	0.4%
1Y	-23.1%	-11.2%	12.0%

Return vs Industry: 1530 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.

Return vs Market: 1530 underperformed the Hong Kong Market which returned 12% over the past year.

Price Volatility

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement	6.9%
Biotechs Industry Average Movement	10.9%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1530's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	5,607	Jing Lou	www.3sbio.com

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.

3SBio Inc. Fundamentals Summary

How do 3SBio's earnings and revenue compare to its market cap?
1530 fundamental statistics
Market cap	HK$13.78b
Earnings (TTM)	HK$1.78b
Revenue (TTM)	HK$9.05b

7.5x

P/E Ratio

1.5x

P/S Ratio

Is 1530 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1530 income statement (TTM)
Revenue	CN¥8.42b
Cost of Revenue	CN¥1.18b
Gross Profit	CN¥7.24b
Other Expenses	CN¥5.58b
Earnings	CN¥1.66b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.70
Gross Margin	85.94%
Net Profit Margin	19.69%
Debt/Equity Ratio	24.7%

How did 1530 perform over the long term?

See historical performance and comparison

Dividends

4.3%

Current Dividend Yield

33%

Payout Ratio

1530 Stock Overview

Rewards

Risk Analysis

3SBio Inc. Competitors

SEHK:6826

HK$14.8b

SEHK:2696

HK$11.1b

SEHK:6955

HK$4.6b

SEHK:1061

HK$1.5b

Price History & Performance

Recent News & Updates

Investor sentiment deteriorates as stock falls 17%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Recent updates

Investor sentiment deteriorates as stock falls 17%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021